UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
19
December 2024 - “Director/PDMR
Shareholding”
|
99.1
Haleon
plc: Director/PDMR
Shareholding
19 December 2024: Haleon plc (the "Company" or "Haleon")
(LSE/NYSE:HLN) today announces notification and public disclosure
in accordance with the requirements of The UK Market Abuse
Regulation of Transactions by Persons Discharging Managerial
Responsibilities ("PDMRs").
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||||
|
a)
|
Name
|
Adrian
Morris
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
General
Counsel - PDMR
|
|||
|
b)
|
Initial
notification /Amendment
|
Initial
Notification
|
|||
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
||||
|
a)
|
Name
|
Haleon
plc
|
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||||
|
a)
|
Description
of the financial instrument, type of
instrument
|
Ordinary
Shares of £0.01 each
|
|||
|
|
|
||||
|
Identification
code
|
GB00BMX86B70
|
||||
|
|
|
||||
|
b)
|
Nature
of the transaction
|
Grant
of a 3-year option over Ordinary Shares under the 2024 Haleon Share
Save Plan which will first become exercisable 1 February
2028.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
£3.00
|
6,150
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|||
|
|
|
||||
|
-
Aggregated volume
|
|
||||
|
|
|
||||
|
-
Price
|
|
||||
|
|
|
||||
|
e)
|
Date of
the transaction
|
19
December 2024
|
|||
|
f)
|
Place
of the transaction
|
Outside
a trading venue
|
|||
Amanda Mellor
Company Secretary
About Haleon
Haleon
(LSE/NYSE: HLN) is a global leader in consumer health, with a
purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date: December 19,
2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|